AL137-ABC
/ Alector
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 07, 2026
Recent Program Updates
(GlobeNewswire)
- "Alector continues to advance AL037/AL137...The company is targeting an IND submission in Q1 2027...Alector continues to advance AL064/AL164, its ABC-enabled tau siRNA program for the treatment of AD and other tauopathies....In addition to AL164, the company is advancing early-stage siRNA programs toward lead candidate selection, including ADP062-ABC, an alpha-synuclein siRNA for PD and ADP065-ABC, an NLRP3 siRNA for multiple neurodegenerative conditions, reflecting the broad applicability of the ABC platform across disease mechanisms."
IND • Pipeline update • Alzheimer's Disease • Parkinson's Disease
November 06, 2025
Alector Brain Carrier: Preclinical and Research Pipeline - AL137
(GlobeNewswire)
- "Alector has selected lead candidate AL137 for its ABC-enabled anti-amyloid beta (Aβ) antibody in Alzheimer’s disease (AD) and is advancing it toward investigational new drug (IND)-enabling studies. The company is targeting an IND filing for AL137 in 2026."
IND • Alzheimer's Disease
1 to 2
Of
2
Go to page
1